Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

被引:25
|
作者
Schjesvold, Fredrik [1 ,2 ]
Richardson, Paul G. [3 ]
Facon, Thierry [4 ]
Alegre, Adrian [5 ,6 ]
Spencer, Andrew [7 ]
Jurczyszyn, Artur [8 ]
Sunami, Kazutaka [9 ]
Frenzel, Laurent [10 ]
Min, Chang-Ki [11 ,12 ]
Guillonneau, Sophie [13 ]
Lin, Peggy L. [14 ]
Le-Guennec, Solenn [15 ]
Campana, Frank [16 ]
van de Velde, Helgi [16 ]
Bensfia, Samira [14 ]
Bringhen, Sara [17 ]
机构
[1] Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway
[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Lille Univ Hosp, Lille, France
[5] Hosp Univ La Princesa, Madrid, Spain
[6] Hosp Quironsalud, Madrid, Spain
[7] Monash Univ, Alfred Hlth, Dept Clin Hematol, Melbourne, Vic, Australia
[8] Jagiellonian Univ, Coll Med, Dept Hematol, Krakow, Poland
[9] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan
[10] Hop Necker Enfants Malad, Paris, France
[11] Catholic Hematol Hosp, Dept Hematol, Seoul, South Korea
[12] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Leukemia Res Inst, Seoul, South Korea
[13] Sanofi CMO, Chilly Mazarin, France
[14] Sanofi Global Oncol, Cambridge, MA USA
[15] Sanofi R&D, Vitry Sur Seine, France
[16] Sanofi R&D, Cambridge, MA USA
[17] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Myeloma Unit, Div Hematol, Turin, Italy
关键词
SAR650984;
D O I
10.3324/haematol.2020.253450
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1182 / 1187
页数:6
相关论文
共 50 条
  • [1] Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Schjesvold, Fredrik
    Bringhen, Sara
    G. Richardson, Paul
    Perrot, Aurore
    Leleu, Xavier
    Moreau, Philippe
    A. Dimopoulos, Meletios
    Hulin, Cyrille
    Tekle, Christina
    Foster, Meredith C.
    Poole, Elizabeth M.
    van de Velde, Helgi
    Facon, Thierry
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : E423 - E427
  • [2] Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis
    Schjesvold, Fredrik H.
    Richardson, Paul G.
    Attal, Michel
    Facon, Thierry
    Alegre, Adrian
    Spencer, Andrew
    Jurczyszyn, Artur
    Sunami, Kazutaka
    Frenzel, Laurent
    Min, Chang-Ki
    Le-Guennec, Solenn
    Campana, Frank
    van de Velde, Helgi
    Bensfia, Samira
    Bringhen, Sara
    BLOOD, 2019, 134
  • [3] Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
    Dimopoulos, Meletios A.
    Leleu, Xavier
    Moreau, Philippe
    Richardson, Paul G.
    Liberati, Anna Marina
    Harrison, Simon J.
    Prince, H. Miles
    Ocio, Enrique M.
    Assadourian, Sylvie
    Campana, Frank
    Malinge, Laure
    Semiond, Dorothee
    van de Velde, Helgi
    Yong, Kwee
    LEUKEMIA, 2021, 35 (02) : 562 - 572
  • [4] Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
    Meletios A. Dimopoulos
    Xavier Leleu
    Philippe Moreau
    Paul G. Richardson
    Anna Marina Liberati
    Simon J. Harrison
    H. Miles Prince
    Enrique M. Ocio
    Sylvie Assadourian
    Frank Campana
    Laure Malinge
    Dorothée Sémiond
    Helgi van de Velde
    Kwee Yong
    Leukemia, 2021, 35 : 562 - 572
  • [5] Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis (vol 106, pg 1182, 2021)
    Schjesvold, Fredrik
    Richardson, Paul G.
    Facon, Thierry
    Alegre, Adriaprimen
    Spencer, Andrew
    Jurczyszyn, Artur
    Sunami, Kazutaka
    Frenzel, Laurent
    Min, Chang-Ki
    Guillonneau, Sophie
    Lin, Peggy L.
    Le-Guennec, Solenn
    Campana, Frank
    van de Velde, Helgi
    Bensfia, Samira
    Bringhen, Sara
    HAEMATOLOGICA, 2022, 107 (03) : 774 - 775
  • [6] Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis
    Dimopoulos, Meletios A.
    Leleu, Xavier
    Moreau, Philippe
    Attal, Michel
    Richardson, Paul G.
    Liberati, Anna Marina
    Harrison, Simon J.
    Prince, H. Miles
    Ocio, Enrique M.
    Assadourian, Sylvie
    Campana, Frank
    Malinge, Laure
    van de Velde, Helgi
    Yong, Kwee
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E254 - E254
  • [7] Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
    Sunami, Kazutaka
    Ikeda, Takashi
    Huang, Shang-Yi
    Wang, Ming-Chung
    Koh, Youngil
    Min, Chang Ki
    Yeh, Su-Peng
    Matsumoto, Morio
    Uchiyama, Michihiro
    Iyama, Satoshi
    Shimazaki, Chihiro
    Lee, Jae Hoon
    Kim, Kihyun
    Kaneko, Hitomi
    Kim, Jin Seok
    Lin, Tung-Liang
    Campana, Frank
    Tada, Keisuke
    Iida, Shinsuke
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E751 - E761
  • [8] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
    Bringhen, Sara
    Pour, Ludek
    Vorobyev, Vladimir
    Vural, Filiz
    Warzocha, Krzysztof
    Benboubker, Lotfi
    Koh, Youngil
    Maisnar, Vladimir
    Karlin, Lionel
    Pavic, Michel
    Campana, Frank
    Le Guennec, Solenn
    Menas, Fatima
    van de Velde, Helgi
    Richardson, Paul G.
    LEUKEMIA RESEARCH, 2021, 104
  • [9] Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study
    Ikeda, T.
    Sunami, K.
    Huang, S-Y.
    Wang, M-C.
    Koh, Y. I.
    Min, C. G.
    Yeh, S-P.
    Matsumoto, M.
    Uchiyama, M.
    Iyama, S.
    Shimazaki, C.
    Lee, J. H.
    Kim, K. H.
    Kaneko, H.
    Kim, J. S.
    Lin, T-L.
    Campana, F.
    Tada, K.
    Iida, S.
    Suzuki, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis
    Harrison, Simon J.
    Richardson, Paul G.
    Alegre, Adrian
    Simpson, David
    Wang, Ming Chung
    Spencer, Andrew
    Delimpasi, Sossana
    Hulin, Cyrille
    Sunami, Kazutaka
    Facon, Thierry
    Vlummens, Philip
    Yong, Kwee
    Campana, Frank
    Inchauspe, Marlene
    Mace, Sandrine
    Risse, Marie-Laure
    van de Velde, Helgi
    Attal, Michel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E33 - E33